Pfizer reported strong mid-stage weight loss trial results for its monthly obesity drug and posted fourth-quarter earnings that beat analyst estimates, signaling progress in its obesity pipeline.
Global pharmaceutical company Pfizer (NYSE:PFE) announced better-than-expected revenue in Q4 CY2025, but sales fell by 1.2% year on year to $17.56 billion. The company expects the full year’s revenue to be around $61 billion, close to analysts’ estimates. Its non-GAAP profit of $0.66 per share was 16.2% above analysts’ consensus estimates.
As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those struggling to navigate the steepest regulatory and patent hurdles in a generation. With major reports from Eli
UK regulators ruled Sanofi breached industry rules over RSV claims in a newspaper interview, following a complaint from Pfizer about Beyfortus promotion.
Large-cap biopharma offers stable growth and dividends, outperforming the S&P 500 in early 2026. With Gilead up 46% and Pfizer
yielding 6%, the sector remains a key volatility hedge following successful U.S. manufacturing negotiations.
Last week we saw a plethora of important earnings results and increased market volatility. This wee should be another busy one with a lot of important companies due to report.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
